Figure 5.
Graphic representation of BIND-014 composed of a biodegradable and hydrophobic PLA polymeric core and a hydrophilic PEG corona decorated with small-molecule (a pseudomimetic PSMA-directed dipeptide) targeting ligands, and a semisynthetic taxane (docetaxel) as an encapsulated anticancer drug.
Note: Images adapted with the permission of BIND Therapeutics (by Gael McGill), Harvard Medical School, and Digizyme Inc.
Abbreviations: PLA, poly(lactic acid); PEG, poly(ethylene glycol); PSMA, prostate-specific membrane antigen.
